The bill amends various sections of Alaska's pharmacy laws to enhance the role of pharmacists in prescribing and administering medications, particularly in relation to controlled substances and opioid management. Key provisions include the requirement for pharmacists to register with the controlled substance prescription database when prescribing or dispensing certain controlled substances. Additionally, the bill mandates that applicants for pharmacist licensure must receive education in pain management and opioid use and addiction, unless they can demonstrate otherwise. Continuing education requirements for license renewal will also include at least two hours focused on pain management and opioid use, with exemptions available under specific conditions.

Furthermore, the bill introduces new standards for pharmacists to provide patient care services under collaborative practice agreements, emphasizing the importance of recognizing their educational limits and consulting with other practitioners as necessary. It also clarifies the definition of the "practice of pharmacy" to include independent prescribing and administration of drugs, as well as the provision of patient care services. The effective date for these changes is set for January 1, 2026.

Statutes affected:
SB0147A, AM SB 147, introduced 03/26/2025: 08.80.030, 17.30.200, 08.80.168, 17.22.020, 17.20.085, 08.80.159, 08.80.110, 08.80.145, 08.80.165, 08.80.337, 08.80.480